Verve Therapeutics, Inc. Overview
Pro stress-test →Verve Therapeutics was a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease. The company specialized in in vivo base editing technology targeting genetic drivers of disease, with its lead program VERVE-102 addressing PCSK9 for cholesterol management.
Strategic Profile
Pro stress-test →Verve focused on breakthrough gene-editing approaches to cardiovascular disease rather than traditional pharma models, positioning itself at the frontier of genetic medicine. The company achieved key regulatory milestones, receiving FDA Fast Track designation for VERVE-102 in April 2025, before its acquisition by Eli Lilly.
Competitive Landscape
Pro stress-test →Verve competed in the genetic medicine space against companies like Beam Therapeutics, Prime Medicine, and CRISPR Therapeutics, which also pursue gene-editing approaches. Traditional cardiovascular pharma (Amgen, Regeneron) dominates the PCSK9 inhibitor market with established drugs, making Verve's in vivo approach a potential disruptor if successfully developed.
Industry Context
Verve Therapeutics, Inc. operates in Genetic Medicine / Gene Editing Therapeutics.
Key facts
Founded: 2018 · Headquarters: Cambridge, US · Employees: 274 · Revenue: N/A · Market cap: ~$0.99B (at acquisition)